Loading...
Please wait, while we are loading the content...
Similar Documents
Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
| Content Provider | MDPI |
|---|---|
| Author | Occhipinti, Mario Brambilla, Marta Galli, Giulia Manglaviti, Sara Giammaruco, Maristella Prelaj, Arsela Ferrara, Roberto Toma, Alessandro De Proto, Claudia Beninato, Teresa Zattarin, Emma Russo, Giuseppe Lo Gelibter, Alain Simmaco, Maurizio Preissner, Robert Garassino, Marina Braud, Filippo De Marchetti, Paolo |
| Copyright Year | 2021 |
| Description | (1) Background. The onset of a drug–drug interaction (DDI) may affect treatment efficacy and toxicity of advanced non-small-cell lung cancer (aNSCLC) patients during epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) use. Here we present the use of $Drug-PIN^{®}$ (Personalized Interactions Network) software to detect DDIs in aNSCLC patients undergoing EGFR-TKIs. (2) Methods. We enrolled patients with Stage IV aNSCLC already treated with or candidates to receive EGFR-TKIs, in any line; ECOG PS 0–2; taking at least one concomitant drug. Cancer treatments, concomitant drugs, and clinical and laboratory data were collected and inserted in $Drug-PIN^{®}$. (3) Results. Ninety-two patients, median age of 68.5 years (range 43–89), were included. In total, 20 clinically relevant DDIs needing medical intervention in a total of 14 patients were identified; the 14 major DDIs were related to a high-grade interaction between TKIs and SSRIs, antipsychotics, antiepileptics, H2-receptor antagonist and calcium antagonists. A negative association between statin intake and PFS was identified (p = 0.02; HR 0.281, 95% CI 0.096–0.825). (4) Conclusions. This is the first retrospective study assessing the prevalence of DDIs, the clinical need for medical intervention and the impact of concomitant drugs on EGFR-TKIs survival in aNSCLC. |
| Starting Page | 424 |
| e-ISSN | 20754426 |
| DOI | 10.3390/jpm11050424 |
| Journal | Journal of Personalized Medicine |
| Issue Number | 5 |
| Volume Number | 11 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-05-18 |
| Access Restriction | Open |
| Subject Keyword | Journal of Personalized Medicine Oncology Drug–drug Interactions (ddi) Egfr Tyrosine-kinase Inhibitors (egfr-tkis) Non-small-cell Lung Cancer (nsclc) Drug-pin® |
| Content Type | Text |
| Resource Type | Article |
